What is Arkuda Therapeutics?
Arkuda Therapeutics is a biotechnology firm dedicated to advancing treatments for neurodegenerative conditions by leveraging novel insights into lysosomal biology. The company's primary focus is on its lead program targeting GRN-related frontotemporal dementia (FTD-GRN), a genetically defined subtype of the disease caused by mutations in the progranulin (GRN) gene. Arkuda's therapeutic compounds are designed to correct progranulin deficiency and address lysosomal dysfunction. Beyond FTD-GRN, Arkuda is exploring the potential of its molecules in genetically defined Parkinson's disease and other neurodegenerative disorders, aiming to enhance the activity of key lysosomal enzymes like beta-glucocerebrosidase (GCase).
How much funding has Arkuda Therapeutics raised?
Arkuda Therapeutics has raised a total of $108M across 2 funding rounds:
Series A
$44M
Series B
$64M
Series A (2019): $44M with participation from Tekla Capital Management LLC, Pfizer Ventures, Atlas Venture, and BioInnovation Capital
Series B (2022): $64M led by Pivotal Bioventure Partners, Surveyor Capital, Eli Lilly, and Cormorant Asset Management
Key Investors in Arkuda Therapeutics
Pivotal Bioventure Partners
Pivotal Life Sciences is a global healthcare investment firm that supports companies developing high impact therapeutics to address major unmet medical needs. They specialize in providing capital to innovative companies developing therapeutic products and capturing investment opportunities with publicly traded life sciences firms.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Tekla Capital Management LLC
Aberdeen Investments is a global specialist asset manager dedicated to providing investment solutions across various asset classes, catering to individual investors, financial advisors, and institutional clients. Their offerings include mutual funds, closed-end funds, exchange-traded funds (ETFs), and separately managed accounts, all supported by a network of over 500 financial professionals.
What's next for Arkuda Therapeutics?
The recent major strategic investment signals a pivotal stage for Arkuda Therapeutics, likely enabling the company to accelerate its clinical development pipeline and expand its research into broader neurodegenerative indications. This substantial backing from prominent life science investors suggests confidence in Arkuda's scientific approach and the significant unmet need in treating diseases like FTD-GRN and Parkinson's. The company is poised to further its mission of transforming the trajectory of neurodegenerative disease through innovative therapeutic solutions.
See full Arkuda Therapeutics company page
